Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Zoetis stock in Canada | $206.31
Own Zoetis shares in just a few minutes.
Zoetis Inc is a drug manufacturers-specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 11,300 staff and has a trailing 12-month revenue of around USD$7.4 billion.
How to buy shares in Zoetis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZTS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Zoetis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Zoetis?
- Has coronavirus impacted Zoetis shares?
- Zoetis shares summary
- Compare share dealing platforms
- Is Zoetis stock a buy or sell?
- Zoetis performance over time
- Can I short Zoetis shares?
- Is Zoetis suitable for ethical investing?
- Are Zoetis shares over-valued?
- Zoetis's financials
- How volatile are Zoetis shares?
- Does Zoetis pay a dividend?
- Other common questions
How has Coronavirus impacted Zoetis's stock price?
Since the stock market crash in March caused by coronavirus, Zoetis's stock price has had significant positive movement.
Its last market close was $206.31, which is 31.06% up on its pre-crash value of $142.23 and 128.88% up on the lowest point reached during the March crash when the stocks fell as low as $90.14.
If you had bought $1,000 worth of Zoetis stocks at the start of February 2020, those stocks would have been worth $683.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,522.57.
Zoetis stock priceUse our graph to track the performance of ZTS stocks over time.
Zoetis shares at a glance
|Latest market close||$206.31|
|52-week range||$141.02 - $210.10|
|50-day moving average||$201.36|
|200-day moving average||$188.18|
|Wall St. target price||$224.58|
|Dividend yield||$0.9 (0.45%)|
|Earnings per share (TTM)||$3.99|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Zoetis price performance over time
|1 week (2021-10-13)||4.48%|
|1 month (2021-09-21)||2.64%|
|3 months (2021-07-21)||4.18%|
|6 months (2021-04-21)||21.25%|
|1 year (2020-10-21)||28.00%|
|2 years (2019-10-21)||63.16%|
|3 years (2018-10-19)||125.55%|
|5 years (2016-10-21)||305.01%|
Is Zoetis under- or over-valued?
Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zoetis's P/E ratio
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Zoetis shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's PEG ratio
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.8187. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 billion.
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7.4 billion|
|Operating margin TTM||36.21%|
|Gross profit TTM||$4.6 billion|
|Return on assets TTM||12.36%|
|Return on equity TTM||51.94%|
|Market capitalisation||$95.8 billion|
TTM: trailing 12 months
Shorting Zoetis shares
There are currently 3.7 million Zoetis shares held short by investors – that's known as Zoetis's "short interest". This figure is 25.1% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.
Zoetis's "short interest ratio" (SIR)
Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 1.5 million). Zoetis's SIR currently stands at 2.5. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2500 shares are currently held short.
However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.0078% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.
Zoetis's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Zoetis's total ESG risk score
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Zoetis's environmental score
Environmental score: 2.72/100
Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Zoetis's social score
Social score: 13/100
Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Zoetis's governance score
Governance score: 8.87/100
Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Zoetis's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.
Zoetis share dividends
Dividend payout ratio: 22.42% of net profits
Recently Zoetis has paid out, on average, around 22.42% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.49% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.9 per share.
While Zoetis's payout ratio might seem low, this can signify that Zoetis is investing more in its future growth.
Zoetis's most recent dividend payout was on 1 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 20 July 2021 (the "ex-dividend date").
Zoetis share price volatility
Over the last 12 months, Zoetis's shares have ranged in value from as little as $141.0212 up to $210.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.654. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists.
Stocks similar to Zoetis
Frequently asked questions
Zoetis in the news
Polen Capital Focus Growth Portfolio Manager Commentary Q3 2021
Polen Capital Global Growth Portfolio Manager Commentary Q3 2021
These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Safely
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Cue Health—developer of a COVID-19 self-testing kit with conditional approval in the US, Canada, European Union and India—has gone public. Here’s how to buy in.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
How to buy Fluence Energy (FLNC) stock in Canada when it goes public
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
How to buy GlobalFoundries (GFS) stock in Canada when it goes public
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
How to buy LianBio (LIAN) stock in Canada when it goes public
Everything we know about the LianBio IPO, plus information on how to buy in.
How to buy Rent the Runway (RENT) stock in Canada when it goes public
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
How to buy Solo Brands (DTC) stock in Canada when it goes public
Everything we know about the Solo Brands IPO, plus information on how to buy in.
How to buy Udemy (UDMY) stock in Canada when it goes public
Everything we know about the Udemy IPO, plus information on how to buy in.
How to buy Arteris (AIP) stock in Canada when it goes public
Everything we know about the Arteris IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.